Nektar Therapeutics (NKTR) Director Robert Chess Sells 5,000 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) Director Robert Chess sold 5,000 shares of Nektar Therapeutics stock in a transaction on Monday, April 17th. The stock was sold at an average price of $18.72, for a total transaction of $93,600.00. Following the sale, the director now owns 276,623 shares in the company, valued at approximately $5,178,382.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 3.01% during midday trading on Thursday, hitting $19.17. 3,035,618 shares of the stock traded hands. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The stock has a 50 day moving average of $18.92 and a 200 day moving average of $14.75. The company’s market capitalization is $2.95 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. The firm had revenue of $37.45 million for the quarter, compared to analyst estimates of $40.83 million. During the same period in the previous year, the business posted ($0.40) earnings per share. The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities research analysts predict that Nektar Therapeutics will post ($1.20) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Director Robert Chess Sells 5,000 Shares of Stock” was originally posted by WKRB News and is the property of of WKRB News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at http://www.wkrb13.com/markets/2065160/nektar-therapeutics-nktr-director-robert-chess-sells-5000-shares-of-stock.html.

Hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its stake in shares of Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock worth $188,481,000 after buying an additional 749,496 shares during the last quarter. Camber Capital Management LLC raised its stake in shares of Nektar Therapeutics by 87.5% in the fourth quarter. Camber Capital Management LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock worth $73,620,000 after buying an additional 2,800,000 shares during the last quarter. State Street Corp raised its stake in shares of Nektar Therapeutics by 21.9% in the fourth quarter. State Street Corp now owns 4,062,468 shares of the biopharmaceutical company’s stock worth $49,839,000 after buying an additional 730,836 shares during the last quarter. RA Capital Management LLC raised its stake in shares of Nektar Therapeutics by 13.6% in the third quarter. RA Capital Management LLC now owns 3,664,154 shares of the biopharmaceutical company’s stock worth $62,950,000 after buying an additional 439,300 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of Nektar Therapeutics by 1.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,353,625 shares of the biopharmaceutical company’s stock worth $57,615,000 after buying an additional 61,918 shares during the last quarter. 86.80% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on NKTR shares. Aegis reiterated a “buy” rating and set a $21.00 price target on shares of Nektar Therapeutics in a research note on Wednesday, December 28th. BTIG Research started coverage on shares of Nektar Therapeutics in a research note on Friday, January 6th. They set a “buy” rating and a $22.00 price target on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 price target (up previously from $15.00) on shares of Nektar Therapeutics in a research note on Friday, March 3rd. Roth Capital set a $23.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 4th. Finally, JPMorgan Chase & Co. set a $24.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Nektar Therapeutics presently has an average rating of “Buy” and an average target price of $25.50.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

5 Day Chart for NASDAQ:NKTR

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065160/nektar-therapeutics-nktr-director-robert-chess-sells-5000-shares-of-stock.html

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.